# Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

*biotech · news · 2026-05-21 · The Manila Times*

## Key points

- The Phase III OptiTROP-Breast03 trial of sac-TMT met its primary endpoint of PFS in first-line TNBC.
- Sac-TMT showed statistically significant and clinically meaningful PFS improvement over chemotherapy in TNBC.
- No new safety signals were observed for sac-TMT in this first-line TNBC Phase III trial.
- Kelun-Biotech will now discuss the regulatory pathway with Chinese authorities based on these results.
- Sac-TMT is the world's first TROP2 ADC approved for lung cancer and now has four indications in China.

**Companies:** Merck & Co., Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
**Countries:** China, USA

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/21/tmt-newswire/pr-newswire/kelun-biotech-announces-phase-iii-trial-of-sacituzumab-tirumotecan-sac-tmt-versus-chemotherapy-as-firstline-treatment-for-advanced-tnbc-met-primary-endpoint-of-pfs/2349405)

---

Canonical: https://newsio.io/n/64248951-e459-40dc-866f-b4af4cc2aad7/sichuan-kelun-biotech-biopharmaceutical-co-ltd
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works